SQI Diagnostics Inc. (TSX-V: SQD), a life sciences and
diagnostics company that develops and commercializes proprietary
technologies and products for advanced microarray diagnostics, today
announced that it has received approval from the TSX Venture Exchange to
extend the expiry of 2,276,000 outstanding common share purchase
warrants (“the Warrants”) of the Company, which were issued in
connection with the Company’s October 2011 private placement financing.
Each warrant, as amended, entitles the holder thereof to purchase one
common share of the Company at a price of $2.50 per common share at any
time until the close of business on October 25, 2016, provided that if
on any day that is 12 months following October 26, 2011 the 20-day
volume weighted average trading price of the Common Shares on the TSX
Venture Exchange equals or exceeds $3.25, then upon the Corporation
sending the Holder written notice of such date and issuing a news
release announcing such date, the Warrants shall only be exercisable for
a period of 30 days following the date on which such written notice is
sent to the Holder.
About SQI Diagnostics
SQI Diagnostics is a life sciences and
diagnostics company that develops and commercializes proprietary
technologies and products for advanced microarray diagnostics. The
Company’s proprietary microarray tests and fully-automated systems are
designed to simplify protein and antibody testing workflow, increase
throughput, reduce costs and provide excellent data quality. For more
information, please visit www.sqidiagnostics.com.
FORWARD-LOOKING INFORMATION
This press release
contains certain forward-looking statements, including, without
limitation, statements containing the words “may”, “plan”, “will”,
“estimate”, “continue”, “anticipate”, “intend”, “expect”, “believe”, “in
the process”, “is subject to” and other similar expressions which
constitute “forward-looking information” within the meaning of
applicable securities laws. Forward-looking statements reflect the
Company's current expectation and assumptions, and are subject to a
number of risks and uncertainties that could cause actual results to
differ materially from those anticipated. These forward-looking
statements involve risks and uncertainties including, but not limited
to, the ability of our patents to adequately protect our rights or
permit us to gain or keep any competitive advantage, and our ability to
market and sell our novel multiplexing technologies and detection
platforms. Such statements reflect the current views of the Company with
respect to future events and are subject to certain risks and
uncertainties and other risks detailed from time-to-time in the
Company’s ongoing filings with the securities regulatory authorities,
which filings can be found at www.sedar.com.
Actual results, events, and performance may differ materially. Readers
are cautioned not to place undue reliance on these forward-looking
statements. The Company undertakes no obligation to publicly update or
revise any forward-looking statements either as a result of new
information, future events or otherwise, except as required by
applicable securities laws.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
Copyright Business Wire 2013